Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Redness-Relief drop help glaucoma eyes without side effects?

NCT ID NCT04007276

Symptom relief Sponsor: Tulane University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether Lumify, a low-dose brimonidine eye drop already approved for redness, can safely reduce eye redness and eyelid droop in 60 glaucoma patients who already use stronger brimonidine drops. Researchers will measure redness, eye pressure, and eyelid position after a single dose. The goal is to see if this lower concentration can relieve a common side effect without harming glaucoma control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brimonidine tartrate ophthalmic solution 0.025% (Lumify)
What this could lead to
If it works, this could offer glaucoma patients a way to reduce eye redness without raising eye pressure or causing droopy eyelids.
What could go wrong
This is a small, early-phase trial with only 60 participants. The lower dose may not work as well as expected, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jun 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Diagnosis of primary open angle glaucoma * Willing and able to give informed consent * Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use Exclusion Criteria: * Pregnancy * Prisoners * Known allergy or sensitivities to brimonidine * No surgery within the past 6 months * No history of lid surgery or botox * Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator * Inability to sit comfortably for 30 minutes * Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Droopy eyelid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma ptosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Droopy eyelid Glaucoma Glaucoma, open-angle Glaucoma, primary open angle Glaucoma; drugs PTOSIS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tulane University Medical Center

    New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.